Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor

Journal of Medicinal Chemistry

Volumn 58, Issue 10, 2015, Pages 4220-4229

  Burford, Neil T ^a   Livingston, Kathryn E ^b   Canals, Meritxell ^c   Ryan, Molly R ^d   Budenholzer, Lauren M L ^d   Han, Ying ^a   Shang, Yi ^e   Herbst, John J ^a   OConnell, Jonathan ^f   Banks, Martyn ^a   Zhang, Litao ^a   Filizola, Marta ^e   Bassoni, Daniel L ^g   Wehrman, Tom S ^f   Christopoulos, Arthur ^c   Traynor, John R ^b   Gerritz, Samuel W ^a   Alt, Andrew ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MONASH UNIVERSITY   (Australia)

^d YALE UNIVERSITY   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f FORMA Therapeutics ^*  (United States)

^g DiscoveRx Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3,6,6 TETRAMETHYL 9 [4 [(2 METHYLBENZYL)OXY]PHENYL] 3,4,5,6,7,9 HEXAHYDRO 1H XANTHENE 1,8(2H) DIONE; 9 [4 [(2 BROMOBENZYL)OXY]PHENYL] 3,3,6,6 TETRAMETHYL 3,4,5,6,7,9 HEXAHYDRO 1H XANTHENE 1,8(2H) DIONE; BETA ARRESTIN; CYCLIC AMP; DELTA OPIATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LEUCINE ENKEPHALIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OPIATE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; 1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 4-(ALPHA-(4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL)-N,N-DIETHYLBENZAMIDE; BENZAMIDE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PIPERAZINE DERIVATIVE; PROTEIN BINDING; QUINOLINE DERIVATIVE; RETINA S ANTIGEN;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CAMP ASSAY; CHO CELL LINE; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; FEMALE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING COMPETITION; CELL MEMBRANE; CHEMICAL STRUCTURE; CRICETULUS; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; SYNTHESIS;

ANIMALS; ARRESTINS; BENZAMIDES; BINDING, COMPETITIVE; CELL MEMBRANE; CHEMISTRY TECHNIQUES, SYNTHETIC; CHO CELLS; CRICETULUS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENKEPHALIN, LEUCINE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PIPERAZINES; PROTEIN BINDING; QUINOLINES; RECEPTORS, OPIOID, DELTA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84930645010     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00007     Document Type: Article

References (33)

1. Gaveriaux-Ruff, C.; Kieffer, B. L. Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches Behav. Pharmacol. 2011, 22 (5-6) 405-414
2. Lutz, P. E.; Kieffer, B. L. Opioid receptors: distinct roles in mood disorders Trends Neurosci. 2013, 36 (3) 195-206
3. Broom, D. C.; Nitsche, J. F.; Pintar, J. E.; Rice, K. C.; Woods, J. H.; Traynor, J. R. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice J. Pharmacol. Exp. Ther. 2002, 303 (2) 723-729
4. Jutkiewicz, E. M.; Rice, K. C.; Traynor, J. R.; Woods, J. H. Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats Psychopharmacology (Berlin, Ger.) 2005, 182 (4) 588-596
5. Le Bourdonnec, B.; Windh, R. T.; Ajello, C. W.; Leister, L. K.; Gu, M.; Chu, G. H.; Tuthill, P. A.; Barker, W. M.; Koblish, M.; Wiant, D. D.; Graczyk, T. M.; Belanger, S.; Cassel, J. A.; Feschenko, M. S.; Brogdon, B. L.; Smith, S. A.; Christ, D. D.; Derelanko, M. J.; Kutz, S.; Little, P. J.; DeHaven, R. N.; DeHaven-Hudkins, D. L.; Dolle, R. E. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859) J. Med. Chem. 2008, 51 (19) 5893-5896
6. Jutkiewicz, E. M.; Baladi, M. G.; Folk, J. E.; Rice, K. C.; Woods, J. H. The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol J. Pharmacol. Exp. Ther. 2006, 317 (3) 1337-1348
7. Chu Sin Chung, P.; Kieffer, B. L. Delta opioid receptors in brain function and diseases Pharmacol Ther 2013, 140 (1) 112-120
8. Chung, P. C. S.; Boehrer, A.; Stephan, A.; Matifas, A.; Scherrer, G.; Darcq, E.; Befort, K.; Kieffer, B. L. Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures Behav. Brain Res. 2014, 278C, 429-434
9. Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing Pharmacol. Rev. 2002, 54 (2) 323-374
10. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51
11. Burford, N. T.; Traynor, J. R.; Alt, A. Positive allosteric modulators of the mu-opioid receptor: a novel approach for future pain medications Br. J. Pharmacol. 2015, 172 (2) 277-286
12. Pradhan, A. A.; Befort, K.; Nozaki, C.; Gaveriaux-Ruff, C.; Kieffer, B. L. The delta opioid receptor: an evolving target for the treatment of brain disorders Trends Pharmacol. Sci. 2011, 32 (10) 581-590
13. Pradhan, A. A.; Smith, M. L.; Kieffer, B. L.; Evans, C. J. Ligand-directed signalling within the opioid receptor family Br. J. Pharmacol. 2012, 167 (5) 960-969
14. Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discovery 2013, 12 (3) 205-216
15. Leach, K.; Loiacono, R. E.; Felder, C. C.; McKinzie, D. L.; Mogg, A.; Shaw, D. B.; Sexton, P. M.; Christopoulos, A. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties Neuropsychopharmacology 2010, 35 (4) 855-869
16. Bassoni, D. L.; Raab, W. J.; Achacoso, P. L.; Loh, C. Y.; Wehrman, T. S. Measurements of beta-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation Methods Mol. Biol. 2012, 897, 181-203
17. Zhao, X.; Jones, A.; Olson, K. R.; Peng, K.; Wehrman, T.; Park, A.; Mallari, R.; Nebalasca, D.; Young, S. W.; Xiao, S. H. A homogeneous enzyme fragment complementation-based beta-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors J. Biomol. Screening 2008, 13 (8) 737-747
18. Burford, N. T.; Wehrman, T.; Bassoni, D.; OConnell, J.; Banks, M.; Zhang, L.; Alt, A. Identification of selective agonists and positive allosteric modulators for mu- and delta-opioid receptors from a single high-throughput screen J. Biomol. Screening 2014, 19 (9) 1255-1265
19. Burford, N. T.; Watson, J.; Bertekap, R.; Alt, A. Strategies for the identification of allosteric modulators of G-protein-coupled receptors Biochem. Pharmacol. 2011, 81 (6) 691-702
20. Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 2007, 28 (8) 382-389
21. Burford, N. T.; Clark, M. J.; Wehrman, T. S.; Gerritz, S. W.; Banks, M.; OConnell, J.; Traynor, J. R.; Alt, A. Discovery of positive allosteric modulators and silent allosteric modulators of the mu-opioid receptor Proc. Natl. Acad. Sci. U.S.A. 2013, 110 (26) 10830-10835
22. Livingston, K. E.; Traynor, J. R. Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor Proc. Natl. Acad. Sci. U.S.A. 2014, 111 (51) 18369-18374
23. Fenalti, G.; Giguere, P. M.; Katritch, V.; Huang, X. P.; Thompson, A. A.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Molecular control of delta-opioid receptor signalling Nature 2014, 506 (7487) 191-196
24. Shang, Y.; LeRouzic, V.; Schneider, S.; Bisignano, P.; Pasternak, G. W.; Filizola, M. Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions Biochemistry 2014, 53 (31) 5140-5149
25. Christopoulos, A.; Changeux, J. P.; Catterall, W. A.; Fabbro, D.; Burris, T. P.; Cidlowski, J. A.; Olsen, R. W.; Peters, J. A.; Neubig, R. R.; Pin, J. P.; Sexton, P. M.; Kenakin, T. P.; Ehlert, F. J.; Spedding, M.; Langmead, C. J. International union of basic and clinical pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands Pharmacol. Rev. 2014, 66 (4) 918-947
26. Ehlert, F. J. Analysis of allosterism in functional assays J. Pharmacol. Exp. Ther. 2005, 315 (2) 740-754
27. Kenakin, T.; Watson, C.; Muniz-Medina, V.; Christopoulos, A.; Novick, S. A simple method for quantifying functional selectivity and agonist bias ACS Chem. Neurosci. 2012, 3 (3) 193-203
28. Pierce, K. L.; Lefkowitz, R. J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors Nat. Rev. Neurosci. 2001, 2 (10) 727-733
29. Vanderah, T. W. Delta and kappa opioid receptors as suitable drug targets for pain Clin. J. Pain 2010, 26 (Suppl. 10) S10-S15
30. Pradhan, A. A.; Smith, M. L.; Zyuzin, J.; Charles, A. delta-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice Br. J. Pharmacol. 2014, 171 (9) 2375-2384
31. Jutkiewicz, E. M. The antidepressant-like effects of delta-opioid receptor agonists Mol. Interventions 2006, 6 (3) 162-169
32. Shelley, J. C.; Cholleti, A.; Frye, L. L.; Greenwood, J. R.; Timlin, M. R.; Uchimaya, M. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules J. Comput.-Aided Mol. Des. 2007, 21 (12) 681-691
33. Greenwood, J. R.; Calkins, D.; Sullivan, A. P.; Shelley, J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution J. Comput.-Aided Mol. Des 2010, 24 (6-7) 591-604